Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.0090 AUD
Change Today +0.001 / 12.50%
Volume 159.0K
As of 12:55 AM 04/1/15 All times are local (Market data is delayed by at least 15 minutes).

bone medical ltd (BNE) Snapshot

Open
A$0.0080
Previous Close
A$0.0080
Day High
A$0.0090
Day Low
A$0.0080
52 Week High
04/4/14 - A$0.03
52 Week Low
12/9/14 - A$0.0040
Market Cap
2.3M
Average Volume 10 Days
910.4K
EPS TTM
A$-0.0091
Shares Outstanding
257.8M
EX-Date
03/6/97
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BONE MEDICAL LTD (BNE)

Related News

No related news articles were found.

bone medical ltd (BNE) Related Businessweek News

No Related Businessweek News Found

bone medical ltd (BNE) Details

Bone Medical Ltd, a specialty biopharmaceutical company, develops therapeutics to prevent and/or treat bone and joint diseases and conditions, primarily osteoporosis, osteoarthritis, and rheumatoid arthritis in Australia. The company’s product pipeline consists of Phase II clinical-stage programs and four preclinical programs. Its principal products include CaPTHymone, an oral parathyroid hormone for the treatment of osteoporosis; Capsitonin, an oral calcitonin for the treatment of osteoarthritis pain; and BN006, a synthetic oligopeptide with selective TNF-a and IL-6 inhibitory mechanism and the potential for oral administration. The company also develops BN005/BN008 cell regulators for the treatment of osteoporosis and arthritis. Bone Medical Ltd is based in West Perth, Australia.

bone medical ltd (BNE) Top Compensated Officers

Senior Consultant
Total Annual Compensation: A$135.7K
Compensation as of Fiscal Year 2014.

bone medical ltd (BNE) Key Developments

Bone Medical Limited Announces Unaudited Consolidated Earnings Results for the First Half-Year Ended December 31, 2014

Bone Medical Limited announced unaudited consolidated earnings results for the first half-year ended December 31, 2014. For the half-year, the company reported total revenue from continuing operations AUD 31,169. Loss before income tax expense was AUD 734,676 against AUD 783,423 a year ago. Loss after income tax for the half year was AUD 734,676 or 0.28 cents per basic and diluted share against AUD 683,140 or 0.06 cents per basic and diluted share a year ago. Total comprehensive loss for the half year attributed to members of the company was AUD 734,676 against AUD 683,140 a year ago. Net cash used in operating activities was AUD 965,419 against AUD 307,789 a year ago. The net loss is attributable to expenditure in relation to research and development technologies, settlement of the outstanding debt with AustInvest and general administration costs associated with an ASX listed company.

Bone Medical Ltd. Announces Board Changes

Bone Medical Ltd. announced that Non-Executive Director Dr. Roger New has resigned, effective immediately. Dr. New has stepped down as part of the termination and settlement of the Proxima Group License and Services Agreements. Mr. Phillip Wingate has been appointed as a Non-Executive Director of the company. Mr. Wingate is currently also Company Secretary of ASX listed companies Orinoco Gold Limited and Potash Minerals Limited. Mr. Wingate currently serves as Company Secretary of the Company and will retain this position.

Bone Medical Ltd., Annual General Meeting, Nov 28, 2014

Bone Medical Ltd., Annual General Meeting, Nov 28, 2014., at 09:00 W. Australia Standard Time. Location: Rendezvous Hotel Perth Central. Agenda: To consider the adoption of remuneration report (non-binding); to consider the re-election of directors; to consider the approval of 10% placement capacity - shares; to consider the ratification of prior issue - shares; and to consider the approval of employee option incentive scheme.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BNE:AU A$0.01 AUD +0.001

BNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BNE.
View Industry Companies
 

Industry Analysis

BNE

Industry Average

Valuation BNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BONE MEDICAL LTD, please visit www.bone-ltd.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.